Physician profile
Paul Omastiak
NPI 1821020124
$13,611.04
in general payments reported to CMS, 2019-2025
38 companies · $314 in 2025
The $314 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,580 · 2020: $1,787 · 2021: $2,557 · 2022: $2,525 · 2023: $2,465 · 2024: $1,382 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,161.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,995.34 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,638.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,263.70 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $1,226.53 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $1,095.31 | 2021-2025 | |
| Pfizer INC. | $991.67 | 2019-2025 | |
| Lilly USA, LLC | $786.70 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $642.88 | 2019-2024 | Krystexxa, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $487.06 | 2019-2024 | Xarelto |
| Allergan, INC. | $457.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $376.77 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $366.18 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $337.44 | 2022-2025 | Rexulti |
| Myriad Women'S Health, INC. | $227.92 | 2023 | Myrisk |
| Amarin Pharma, INC. | $224.18 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Omastiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.